Cargando…

Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials

There are inadequate data on the outcomes of patients who declined to participate in randomised clinical trials as compared with those of participants. We retrospectively reviewed the patient characteristics and treatment outcomes of both participants and non-participants in the two randomised trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanai, C, Nokihara, H, Yamamoto, S, Kunitoh, H, Yamamoto, N, Sekine, I, Ohe, Y, Tamura, T
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669997/ https://www.ncbi.nlm.nih.gov/pubmed/19293799 http://dx.doi.org/10.1038/sj.bjc.6604982

Ejemplares similares

Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2011)

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
por: Sekine, I, et al.
Publicado: (2004)

Five‐year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non‐small‐cell lung cancer
por: Kanda, Shintaro, et al.
Publicado: (2020)

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer
por: Goto, K, et al.
Publicado: (2004)

Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer
por: Sekine, I, et al.
Publicado: (2008)

Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma
por: Tamura, Yosuke, et al.
Publicado: (2015)

Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer
por: Nishio, M, et al.
Publicado: (2013)

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702
por: Okamoto, H, et al.
Publicado: (2007)

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer
por: Horinouchi, Hidehito, et al.
Publicado: (2015)

Reply to ‘Malignant pericardial effusion: sclerotherapy or local chemotherapy?’
por: Kunitoh, H, et al.
Publicado: (2009)

A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)
por: Kunitoh, H, et al.
Publicado: (2010)

Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study
por: Kanda, S., et al.
Publicado: (2016)

A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811)
por: Kunitoh, H, et al.
Publicado: (2009)

A randomised phase II trial of preoperative chemotherapy of cisplatin–docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG 0204)
por: Kunitoh, H, et al.
Publicado: (2008)

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507
por: Sekine, I, et al.
Publicado: (2003)

Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
por: Tamura, Nobumasa, et al.
Publicado: (2019)

A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)
por: Kunitoh, H, et al.
Publicado: (2009)

Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies
por: Tanaka, Midori, et al.
Publicado: (2018)

UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial
por: Ichinose, Y, et al.
Publicado: (2005)

Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809
por: Niho, S, et al.
Publicado: (2013)

How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer
por: Kunitoh, H, et al.
Publicado: (2007)

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2016)

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
por: Wakui, Hiroshi, et al.
Publicado: (2014)

Comparing socially disadvantaged smokers who agree and decline to participate in a randomised smoking cessation trial
por: Bonevski, Billie, et al.
Publicado: (2015)

Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma
por: Okuma, Yusuke, et al.
Publicado: (2020)

Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy
por: Moriwaki, Toshikazu, et al.
Publicado: (2016)

Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer
por: Yagishita, Shigehiro, et al.
Publicado: (2015)

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
por: Catalano, V, et al.
Publicado: (2008)

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer
por: Baka, S, et al.
Publicado: (2008)

Randomised study of adjuvant chemotherapy for completely resected p-stage I–IIIA non-small cell lung cancer
por: Nakagawa, K, et al.
Publicado: (2006)

Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer
por: Oshita, F, et al.
Publicado: (2010)

A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors
por: Nokihara, Hiroshi, et al.
Publicado: (2012)

Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies
por: Okuma, H S, et al.
Publicado: (2016)

A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)
por: Hall, P S, et al.
Publicado: (2017)

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
por: Nakamichi, Shinji, et al.
Publicado: (2015)

Integrative prognostic analysis of tumor–infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy
por: Yazaki, Shu, et al.
Publicado: (2022)

Efficacy and safety of second‐line chemotherapy for patients with advanced non‐small cell lung cancer complicated by interstitial lung disease
por: Otsuka, Kenji, et al.
Publicado: (2022)

Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer
por: Meghal, Trishala, et al.
Publicado: (2019)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
por: Morita, Chie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_48i0vbth5puic0q1hodgup24fv